

Childhood ACT Immunisation Schedule

| Age and eligibility | Disease | Brand(s) | Important information |
|---|--|---|--|
| Birth | Hepatitis B | H-B-Vax® II paediatric OR Engerix-B® paediatric | Within 7 days of birth, ideally within 24 hours. |
| 2 months (may be given from 6 weeks) | Diphtheria, tetanus, pertussis, poliomyelitis, <i>Haemophilus influenzae</i> type <i>b</i> (Hib) and hepatitis B | Infanrix® Hexa OR Vaxelis® | |
| | Pneumococcal | Prevenar® 13 | |
| | Rotavirus | Rotarix® (oral) | First dose must be given by 14 weeks of age. |
| | Meningococcal B (Aboriginal and Torres Strait Islander children) | Bexsero® | Prophylactic paracetamol recommended. Also recommended for other children (see AIH). |
| 4 months | Diphtheria, tetanus, pertussis, poliomyelitis, <i>Haemophilus influenzae</i> type <i>b</i> (Hib) and hepatitis B | Infanrix® Hexa OR Vaxelis® | |
| | Pneumococcal | Prevenar® 13 | |
| | Rotavirus | Rotarix® (oral) | Second dose must be given by 24 weeks of age. Minimum interval from dose one is four weeks. |
| | Meningococcal B (Aboriginal and Torres Strait Islander children) | Bexsero® | Prophylactic paracetamol recommended. Also recommended for other children (see AIH). |
| 6 months | Diphtheria, tetanus, pertussis, poliomyelitis, <i>Haemophilus influenzae</i> type <i>b</i> (Hib) and hepatitis B | Infanrix® Hexa OR Vaxelis® | |
| | Pneumococcal (children with specified medical risk conditions) | Prevenar 13® | An additional (3rd) dose of 13vPCV is required for children with specified medical risk conditions (see AIH). |
| | Meningococcal B (Aboriginal and Torres Strait Islander children with specified medical risk conditions) | Bexsero® | Prophylactic paracetamol recommended. See AIH for specified medical risk conditions. |
| 6 months to under 5 years (annually) | Influenza | Age-appropriate influenza vaccine | Administer annually. In children aged 6 months to less than 9 years of age in the first year of administration, give 2 doses, a minimum of 1 month apart. One dose annually in subsequent years. Discuss influenza vaccination with other present family members. |
| 12 months | Measles, mumps, rubella (MMR) | Priorix® or MMRII® | MMRV is <u>not</u> recommended as the first dose of MMR containing vaccine for children under 4 years of age. The first dose <u>must</u> be MMR (at 12 months – Priorix® or MMRII®) and second dose – MMRV (at 18 months – Priorix Tetra®). |
| | Meningococcal ACWY | Nimenrix® | |
| | Pneumococcal | Prevenar®13 | |
| | Meningococcal B (Aboriginal and Torres Strait Islander children) | Bexsero® | Prophylactic paracetamol recommended. Also recommended for other children (see AIH). |
| | Hepatitis B (pre term and low-birthweight infants) | H-B-Vax® II paediatric OR Engerix-B® paediatric | Babies born at less than 32 weeks gestation or less than 2000g birth weight require an extra hepatitis B vaccine at 12 months of age. |
| 18 months | Measles, mumps, rubella and varicella (MMRV) | Priorix-tetra® | |
| | Diphtheria, tetanus, pertussis (DTPa) | Infanrix® or Tripacel® | |
| | <i>Haemophilus influenzae</i> type <i>b</i> (Hib) | Act-HIB® | |
| 4 years | Diphtheria, tetanus, pertussis and poliomyelitis | Infanrix-IPV® or Quadracel® | |
| | Pneumococcal (children with specified medical risk conditions) | Pneumovax 23® | Administer a first dose of 23vPPV at age 4 years, followed by a second dose of 23vPPV at least 5 years later for children with specified medical risk conditions. |
| ≥5 years (annually) | Influenza (children with specified risk conditions) | Age-appropriate influenza vaccine | Administer annually. For children aged >6mths to <9 yrs old, the primary course requires 2 vaccinations a minimum of 4 weeks apart. Subsequent years, one dose annually. |
| | Influenza (Aboriginal and Torres Strait islander people) | Age-appropriate influenza vaccine | |

Adolescent

| Age and eligibility | Disease | Brand(s) | Important information |
|--------------------------------|---|-----------------------------------|--|
| All ages | Influenza (people with specified risk conditions) | Age-appropriate influenza vaccine | Administer annually. Refer to AIH for information on age-appropriate vaccines and follow the ATAGI advice on seasonal influenza vaccines. |
| | Influenza (Aboriginal and Torres Strait islander people) | Age-appropriate influenza vaccine | |
| | Pneumococcal (adolescents with specified medical risk conditions) | Prevenar 13® and Pneumovax 23® | Administer a dose of 13vPCV at diagnosis followed by 2 doses of 23vPPV (see AIH for dose interval). |
| Year 7 (or age equivalent) | Diphtheria, tetanus, pertussis (dTpa) | Boostrix® OR Adacel® | Administered through the High School Immunisation Program. Catch up available through general practitioners and pharmacies up until the person's 20th birthday. |
| | Human Papillomavirus (HPV) | Gardasil 9® | Administered through the High School Immunisation Program. Single dose recommended. People with severely immunocompromising conditions require a 3 dose schedule. Catch up available through general practitioners and pharmacies up until the person's 26th birthday. |
| Year 10 (or age equivalent) | Meningococcal ACWY | MenQuadfi® | Administered through the High School Immunisation Program. Catch up available through general practitioners and pharmacies up until the person's 20th birthday. |

Adult

| Age and eligibility | Disease | Brand(s) | Important information |
|--|--|-----------------------------------|--|
| All ages | Influenza (people with specified risk conditions) | Age-appropriate influenza vaccine | Administer annually. Refer to AIH for information on age-appropriate vaccines and follow the ATAGI advice on seasonal influenza vaccines. |
| | Influenza (Aboriginal and Torres Strait islander people) | Age-appropriate influenza vaccine | |
| Aboriginal and Torres Strait Islander adults 50 years and over | Pneumococcal | Prevenar 13® and Pneumovax 23® | Administer a dose of 13vPCV, followed by first dose of 23vPPV 12 months later (2-12 months acceptable), then second dose of 23vPPV at least 5 years later. |
| | Shingles (herpes zoster) | Shingrix® | Administer 2 doses 2-6 months apart (or 1-2 months apart if immunocompromised or shortly expected to be immunocompromised). |
| All people 65 years and over | Influenza | Age-appropriate influenza vaccine | Administer annually. Follow ATAGI advice on seasonal influenza vaccines. |
| | Shingles (herpes zoster) | Shingrix® | Administer 2 doses 2-6 months apart (or 1-2 months apart if immunocompromised). |
| 70 years and over | Pneumococcal | Prevenar 13® | |
| Pregnant people | Pertussis (whooping cough) | Boostrix® OR Adacel® | Single dose recommended each pregnancy, ideally between 20-32 weeks, but may be given up until delivery. |
| | Influenza | Age-appropriate influenza vaccine | In each pregnancy, at any stage of pregnancy. |
| | Respiratory syncytial virus (RSV) | Abrysvo® | Recommended between 28-36 weeks gestation. Can be co-administered with other maternal vaccines. |

Additional vaccination for people with medical risk conditions

| Age and eligibility | Disease | Brand(s) | Important information |
|----------------------|--|-----------------------------------|--|
| All ages | Meningococcal ACWY | Nimenrix® | For people with asplenia, hyposplenia, complement deficiency and those undergoing treatment with eculizumab. Refer to the AIH for dosing schedule. The number of doses required varies with age. |
| | Meningococcal B | Bexsero® | |
| ≥6 months (annually) | Influenza | Age-appropriate influenza vaccine | For people with specific medical risk conditions that increase their risk of complications from influenza. Refer to the AIH for information on age-appropriate vaccines. |
| <12 months | Pneumococcal | Prevenar 13® and Pneumovax 23® | For people with specific medical risk conditions that increase their risk of pneumococcal disease, an additional (3rd) dose of 13vPCV in infancy, followed by a routine booster dose at age 12 months (as with other healthy children). Refer to AIH. |
| ≥12 months | Pneumococcal | Prevenar 13® and Pneumovax 23® | For people with specific medical risk conditions that increase their risk of pneumococcal disease, administer a dose of 13vPCV at diagnosis. Refer to the AIH for dose intervals. |
| ≥5 years | <i>Haemophilus influenzae</i> type B (Hib) | ACT-Hib® | For people with asplenia and hyposplenia, a single dose is required if the person was not vaccinated in infancy or incompletely vaccinated (note that all children aged <5 years are recommended to complete Hib vaccination regardless of asplenia or hyposplenia). |
| ≥18 years | Shingles | Shingrix® | Eligible people 18 years and over with increased risk due to underlying conditions and/or immunomodulatory/immunosuppressive treatments. Give 2 doses 1-2 months apart. |

ACT funded programs – shows the ACT funded vaccines available for free for eligible people in addition to the National Immunisation Program (NIP) schedule

| Disease | Brand(s) | Eligibility and important information |
|-----------------------------------|-------------------------|--|
| Hepatitis B | As delivered | The Hepatitis B vaccine is funded for: people who inject drugs, and partners and other household and intimate contacts of people who have acute or chronic hepatitis B. |
| Measles mumps rubella | MMRII | Adolescents and adults born during or since 1966 without documented evidence of 2 valid doses of MMR vaccine or serological evidence of immunity. More information can be found on the AIH. |
| Mpox | JYNNEOS® | The groups currently eligible to receive government funded mpox vaccine can be found on the ACT Government website – www.act.gov.au/health/topics/immunisation/mpox-vaccination |
| Japanese encephalitis virus (JEV) | Imojev® or Jespect® | The groups currently eligible to receive a government funded JEV vaccine in the ACT can be found on the ACT Government website – www.act.gov.au/health/topics/immunisation/japanese-encephalitis-virus-jev-vaccination |
| Rabies | As delivered | Post exposure treatment for Australian bat lyssavirus and rabies exposures can be ordered via the ACT Immunisation Section on (02) 5124 9800. |
| Other | As delivered | ACT Health provides vaccines as post-exposure prophylaxis for certain diseases following public health risk assessment. More information can be found on the ACT Government website – www.act.gov.au/health/topics/diseases |
| Respiratory syncytial virus (RSV) | Beyfortus™ (nirsevimab) | Eligibility criteria for infants to receive government funded Beyfortus™ can be found on the ACT Government website – www.act.gov.au/health/providing-health-care-in-the-act/treatment-and-clinical-information/vaccination/rsv-prevention-program-for-healthcare-providers-in-the-act |

All people less than 20 years of age and refugees and humanitarian entrants of all ages are eligible for catch-up vaccines. Gardasil 9® is funded up until a person's 26th birthday.

COVID-19 vaccines – Refer to the Department of Health and Aged Care website – www.health.gov.au/our-work/covid-19-vaccines

Last updated February 2025

For further information

- » refer to the Australian Immunisation Handbook (AIH) – <https://immunisationhandbook.health.gov.au>
- » contact the ACT Immunisation Section on (02) 5124 9800.

